Granisetron reduces clinical and histological response to intra-arterial neoadjuvant chemotherapy in oral squamous cell carcinoma.
Intra-arterial neoadjuvant chemotherapy (TPP) with pirarubicin, cisplatin and peplomycin produced strong primary effects on oral squamous cell carcinoma, using metoclopramide (MCA) as an anti-emetic. After clinical application of granisetron (GRN), the clinical responses to TPP observed previously were weakened. In this paper, the influence of GRN on TPP is discussed. Sixty-three cases were evaluated with regard to the primary effects of TPP and anti-emetics. GRN was used in 42 cases of the GRN group, and MCA in 21 cases of non-GRN group. The clinical response rate (complete response, CR or partial response, PR) was 95.2% in the non-GRN group, and 76.2% in the GRN group. The rate of CR in the non-GRN group was 47.6%, whereas it was 9.5% in the GRN group. The histological effects in the GRN group were significantly lower (P<0.05) than those of non-GRN group. Concerning the relationship between the clinical responses and the histological responses, 4 of the 18 CR+PR cases (22.2%) in the GRN group showed good histological responses, compared with 6 of the 14 CR+PR cases (42.9%) showing in the non-GRN group. The histological responses in the GRN group were significantly lower (P<0.05) than in the non-GRN group. Our data indicate that GRN reduces the clinical and histological responses of chemotherapy.
Shikimori
M
M
Department of Oral & Maxillofacial Surgery, Faculty of Medicine, Saga University, Saga 849-8501, Japan. shikimor@dent.asahi_u.ac.jp
Komatsu
H
H
Hashimoto
K
K
Yamashita
Y
Y
D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D016009:Chi-Square Distribution; D002945:Cisplatin / Q000008:administration & dosage; D015331:Cohort Studies; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D004347:Drug Interactions; D005260:Female; D017829:Granisetron / Q000627:therapeutic use*; D006801:Humans; D007269:Injections, Intra-Arterial; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy*; D017663:Peplomycin / Q000008:administration & dosage; D012189:Retrospective Studies
D000932:Antiemetics; D002945:Cisplatin; D004317:Doxorubicin; D017829:Granisetron; D017663:Peplomycin; C027260:pirarubicin